Glucose and insulin changes in infants and children undergoing hypothermic open-heart surgery

Insights

Hypothermic open-heart surgery causes significant hyperglycemia in pediatric patients due to inadequate insulin response. Restricting intraoperative glucose prevents this hyperglycemia, improving patient outcomes.

Area of Science:

  • Pediatric Cardiac Surgery
  • Metabolic Response to Surgery
  • Anesthesiology

Background:

  • Hypothermic open-heart surgery is associated with marked hyperglycemia in pediatric patients.
  • The underlying mechanisms for this hyperglycemia, particularly in relation to insulin response, require further investigation.

Purpose of the Study:

  • To evaluate the mechanisms responsible for hyperglycemia during hypothermic open-heart surgery in pediatric patients.
  • To assess the relationship between glucose and insulin levels in different surgical scenarios.
  • To provide recommendations for glucose management during pediatric cardiac surgery.

Main Methods:

  • Paired glucose and insulin levels were measured in three groups of pediatric patients undergoing cardiac surgery with varying degrees of hypothermia and circulatory arrest.
  • A fourth group received restricted glucose infusion to assess its impact on hyperglycemia.
  • Analysis of metabolic responses in relation to surgical conditions.

Main Results:

  • All surgical groups exhibited significant hyperglycemia during and after open-heart surgery.
  • Insulin levels did not increase proportionally to the elevated glucose levels, indicating an impaired insulin response.
  • Restricting intraoperative glucose infusion in a separate group prevented the development of hyperglycemia.

Conclusions:

  • Pediatric patients undergoing hypothermic open-heart surgery experience hyperglycemia primarily due to an insufficient insulin response.
  • Intraoperative hyperglycemia can lead to misinterpretation of cardiorenal function due to osmotic diuresis.
  • Recommendations include avoiding glucose in pump prime solutions and intraoperative fluids, opting for balanced electrolyte solutions instead.

Related Concept Videos

Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...